USPTO Examiner LI BAO Q - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19067863Phage Composition and Its Use in Strengthening Soil Carbon FixationMarch 2025October 2025Allow710NoNo
18770056POLYNUCLEOTIDE MOLECULES USED FOR THE PREVENTION OR TREATMENT OF HPV INFECTION RELATED DISEASESJuly 2024March 2025Allow811YesNo
18749700COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUSJune 2024April 2025Allow1001YesNo
18749697COMPOSITIONS AND METHODS FOR AMPLIFYING, DETECTING OR QUANTIFYING HUMAN POLYOMAVIRUS BK VIRUSJune 2024October 2025Allow1611NoNo
18743581SMALLPOX VACCINE FOR CANCER TREATMENTJune 2024January 2026Allow2021NoNo
18670296ONCOLYTIC VIRUS STRAINMay 2024December 2025Allow1911YesNo
18634012ADJUVANT AND VACCINE CONTAINING ADJUVANTApril 2024February 2026Abandon2221NoNo
18609504HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONSMarch 2024October 2025Abandon1901NoNo
18597018Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use ThereofMarch 2024June 2025Allow1511YesNo
18441086SYSTEMS AND PROCESSES TO SCREEN FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) OF 2019 (COVID-19)February 2024May 2025Allow1510NoNo
18437608CONTRACEPTIVE VACCINE BASED ON THE SPERM-ASSOCIATED PROTEIN CATSPERFebruary 2024March 2025Allow1311YesNo
18406869Novel Adjuvant CompositionsJanuary 2024September 2025Allow2011NoNo
18386007APPARATUS FOR DETERMINING ADMINISTRATION FORM OF A COMPOSITION OF AN ENGINEERED VIRUS-BASED NANOPARTICLE FOR A TREATMENT OF AN AUTOIMMUNE CONDITIONNovember 2023September 2025Allow2241YesNo
18491193STABILIZED GROUP 2 INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOFOctober 2023September 2025Allow2311YesNo
18462133MODIFIED ONCOLYTIC VIRUSSeptember 2023July 2025Allow2211NoNo
18458903CD47 TARGETED THERAPIES FOR THE TREATMENT OF INFECTIOUS DISEASEAugust 2023May 2025Allow2120NoNo
18238829SENECA VALLEY VIRUS (SVV) CELLULAR RECEPTOR TARGETED ONCOTHERAPYAugust 2023July 2025Allow2311YesNo
18450908ADJUVANT FOR ANIMAL AND HUMAN VACCINESAugust 2023September 2025Allow2511NoNo
18447439IL-36 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOFAugust 2023September 2025Allow2611YesNo
18365671NOVEL VACCINE ADJUVANTAugust 2023April 2025Allow2011YesNo
18365082RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED NAAugust 2023January 2025Allow1801YesNo
18332291Ebola Virus Antibodies and Binding Agents Derived TherefromJune 2023February 2025Allow2001YesNo
18307593ONCOLYTIC VIRUSES AS ADJUVANTSApril 2023July 2025Abandon2711NoNo
18191625IMMUNO-MODULATED REPLICATION-EFFICIENT VACCINIA VIRUS STRAINMarch 2023January 2025Allow2211YesNo
18187133IDENTIFICATION OF VARIABLE INFLUENZA RESIDUES AND USES THEREOFMarch 2023January 2025Allow2211YesNo
18181754HPV VACCINEMarch 2023April 2025Abandon2511NoNo
18163837ENGINEERED VIRUSFebruary 2023April 2025Allow2660YesNo
18163038Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus AntigensFebruary 2023March 2025Allow2621YesNo
18161210REMOVAL OF AGGLOMERATESJanuary 2023September 2024Allow1911YesNo
18010412SWINE INFLUENZA A VIRUS VACCINE COMPRISING TWO DISTINCT RNA REPLICON PARTICLESDecember 2022January 2026Allow3720YesNo
17993182TUMOR-SELECTIVE E1A AND E1B MUTANTSNovember 2022September 2024Allow2111YesNo
17922670Coronavirus Assays, Diagnostic Methods, Treatment Methods, and Compositions Related TheretoNovember 2022October 2025Allow3600NoNo
18050806THERAPEUTIC AND PREVENTATIVE CANCER VACCINESOctober 2022November 2025Allow3731YesNo
17799464HPV VACCINEAugust 2022March 2026Allow4311NoNo
17798189Vaccine and Methods for Detecting and Preventing FilariasisAugust 2022July 2025Allow3611YesNo
17817245MODIFIED ONCOLYTIC VIRUSAugust 2022October 2024Allow2751YesNo
17811059VIRUS PURIFICATIONJuly 2022September 2024Allow2621NoNo
17788671POLYMERIC NANOPARTICLES FOR ENHANCED CANCER TREATMENTJune 2022February 2026Abandon4401NoNo
17846817REPLICATION-DEFECTIVE ARENAVIRUS VECTORSJune 2022October 2024Allow2811NoNo
17787560NOVEL PRIME-BOOST INFLUENZA VACCINEJune 2022September 2025Allow3910NoNo
17784838MULTIVALENT HVT VECTOR VACCINEJune 2022November 2025Allow4210NoNo
17748715SARS-CoV-2 POLYPEPTIDESMay 2022February 2026Allow4511YesNo
17775475METHOD FOR PRODUCING REASSORTANT INFLUENZA VIRUSESMay 2022November 2025Allow4211YesNo
17607118LIVE IMAGING SYSTEM TO VISUALIZE THE RETRO-TRANSCRIBED VIRAL DNA GENOMEApril 2022December 2025Allow5011NoNo
17726952Immunogenic Compositions Against SARS-COV-2 Variants and Their Methods of UseApril 2022January 2026Abandon4401NoNo
17767291DNA VACCINE CAPABLE OF EFFECTIVELY TREATING AND/OR PREVENTING TYPE 1 DIABETES AND USE THEREOFApril 2022December 2025Allow4411YesNo
17713718IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAMEApril 2022January 2026Abandon4501NoNo
17709009COMBINATION GMCI AND ATRI CANCER TREATMENTMarch 2022January 2026Abandon4501NoNo
17754280tFIBER PROTEIN FRAGMENT OF AVIAN EGG DROP SYNDROME VIRUS AND VACCINE COMPOSITION PREPARED THEREOF, PREPARATION METHOD AND USEMarch 2022August 2025Allow4021YesNo
17764295METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAVMarch 2022October 2025Allow4220YesNo
17761403PRODUCTION AND FUNCTIONALIZATION OF NANOPARTICLES DERIVED FROM PHAGE T5 AND THERAPEUTIC USESMarch 2022October 2025Allow4311YesNo
17642756MODIFIED VESICULAR STOMATITIS VIRUS GLYCOPROTEIN AND USES THEREOF FOR THE TREATMENT OF BRAIN TUMORSMarch 2022November 2025Abandon4401NoNo
17639773SEASONAL INFLUENZA VACCINE CAPABLE OF INDUCING VIRUS-SPECIFIC ANTIBODY INTO NASAL CAVITYMarch 2022October 2025Abandon4310NoNo
17684269ANTIVIRAL VACCINES USING SPHERICAL NUCLEIC ACIDSMarch 2022March 2026Allow4911NoNo
17675535INFLUENZA VACCINE COMPOSITION BASED ON NOVEL NUCLEIC ACIDFebruary 2022September 2025Allow4312NoNo
17629356MULTIMERIC PROTEIN DOMAINS FOR MULTIFUNCTIONALITY AND ENHANCED SECRETION OF THERAPEUTIC PROTEINSJanuary 2022November 2025Abandon4601NoNo
17579459Polyvalent immunogenicity composition for human papillomavirusJanuary 2022May 2025Allow4011NoNo
17626340METHOD FOR VACCINATING AVIANS AGAINST REOVIRUSJanuary 2022October 2025Allow4511YesNo
17626337SENECAVIRUS A VIRUS STRAINS AND IMMUNOGENIC COMPOSITIONS THEREFROMJanuary 2022October 2025Allow4521NoNo
17621816INFLUENZA VIRUS NEURAMINIDASE AND USES THEREOFDecember 2021August 2025Abandon4401NoNo
17618283MUCOSAL VACCINE FORMULATIONSDecember 2021October 2025Allow4721YesNo
17617258INFLUENZA VIRUS BACKBONEDecember 2021March 2025Allow3910YesNo
17616006AAV VECTORS WITH MYELIN PROTEIN ZERO PROMOTER AND USES THEREOF FOR TREATING SCHWANN CELL-ASSOCIATED DISEASES LIKE CHARCOT-MARIE-TOOTH DISEASEDecember 2021November 2025Allow4811YesNo
17541134ANTIVIRAL IMMUNOTHERAPY BY MEMBRANE RECEPTOR LIGATIONDecember 2021January 2026Allow4951YesNo
17607495COMPOSITIONS FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMAOctober 2021September 2025Allow4710NoNo
17600164IMMUNE-STIMULATORY COMPOSITIONS AND USE THEREOFSeptember 2021February 2024Allow2911YesNo
17440546METHOD OF MODULATING MUCOSAL IMMUNOGENICITYSeptember 2021January 2026Allow5221NoNo
17434180NOVEL PLANT GROWTH PROMOTING MICROBIAL COMPOSITIONSAugust 2021January 2025Allow4010YesNo
17443261PEPMIXES TO GENERATE MULTIVIRAL CTLS WITH BROAD SPECIFICITYJuly 2021December 2023Allow2921YesNo
17423849PHLIP®-MEDIATED INTRACELLULAR DELIVERY OF IMMUNO-STIMULATORY COMPOUNDSJuly 2021April 2025Allow4510YesNo
17422641CD200AR LIGANDS FOR CANCER IMMUNOTHERAPYJuly 2021May 2025Allow4621YesNo
17368994VIRAL PREPARATIONS AND METHODS FOR TREATING AND MODULATING MITOCHONDRIAL EFFECTS OF CORONAVIRUS INFECTIONS.July 2021December 2024Allow4151YesNo
17414156SERUM FREE INTRACELLULAR PATHOGEN VACCINEJune 2021October 2025Allow5231YesNo
17413512MEMBRANE BOUND IL12 COMPOSITIONS AND METHODS FOR TUNABLE REGULATIONJune 2021October 2024Allow4010YesNo
17334417CAR-T CELLS WITH HUMANIZED CD19 SCFV WITH MUTATION IN CDR 1 REGIONMay 2021September 2024Allow3910NoNo
17297353BIOMARKERS FOR CD47 BLOCKADE THERAPYMay 2021February 2025Allow4521YesNo
17295287COMPOSITIONS AND METHODS FOR INTERNAL CONTROLS OF MICROVESICLE ISOLATIONSMay 2021November 2024Allow4211YesNo
17275253IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE AND APPLICATION THEREOFMay 2021November 2024Allow4411YesNo
17307066MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONAVIRUSESMay 2021November 2024Allow4230YesNo
17288019MODIFIED PDC LINE FOR SECRETING A CYTOKINEApril 2021December 2024Abandon4420NoNo
17287429SYNP57 (PROA14), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PHOTORECEPTORSApril 2021October 2024Abandon4210NoNo
17232597NOVEL CANCER ANTIGENS AND METHODSApril 2021November 2024Allow4311YesNo
17285874MODIFIED CMV GB PROTEIN AND CMV VACCINE INCLUDING SAMEApril 2021October 2024Allow4211YesNo
17282673METHODS FOR MEASURING THE TITER AND POTENCY OF VIRAL VECTOR PARTICLESApril 2021April 2025Allow4921YesNo
17282172COMPOSITION FOR PREVENTING OR TREATING BENIGN TUMORApril 2021June 2025Allow5030YesNo
17181657SINDBIS CONTROL VIRUSFebruary 2021February 2025Allow4851YesNo
17265498COMPOSITIONS COMPRISING ANNEXIN V AND HPV TUMOR ANTIGEN FUSION POLYPEPTIDES AND METHODS FOR MAKING AND USEFebruary 2021November 2025Allow5721YesYes
17263049TREATMENT OF MUCOPOLYSACCHARIDOSIS IVAJanuary 2021November 2024Allow4611YesNo
17151840PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENSJanuary 2021February 2025Allow4941YesYes
17259849METHODS OF TREATING CANCER WITH TNF EXPRESSING MYXOMA VIRUSJanuary 2021November 2024Allow4611NoNo
17253927ONCOLYTIC VIRUS OR ANTIGEN PRESENTING CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40-LIGANDDecember 2020October 2024Allow4631YesNo
17252123VACCINE VECTOR ENCODING MUTATED GNAQ FOR TREATMENT OF UVEAL MELANOMA AND CANCERS HAVING ONCOGENIC MUTATIONS ON GNAQ AND GNA11 PROTEINSDecember 2020April 2025Abandon5221YesNo
17116538METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERSDecember 2020January 2025Abandon5002YesNo
17056306ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORMNovember 2020April 2025Allow5341YesNo
17044074RECOMBINANT ONCOLYTIC VIRUS COMPOSITION AND USE THEREOFSeptember 2020March 2025Allow5340YesNo
17042822PERSONALIZED CANCER VACCINESSeptember 2020January 2025Allow5211NoNo
16975298PREVENTION OR TREATMENT OF CARDIAC ARRHYTMIA AND SUDDEN CARDIAC DEATHAugust 2020December 2024Abandon5211NoNo
16626019RECOMBINANT ONCOLYTIC VIRUSES FOR TREATMENT OF METASTATIC CANCERSDecember 2019March 2025Allow6051YesNo
16307710METHOD FOR THE DETECTION OF AN IGM ANTIBODY SPECIFIC FOR A FLAVIVIRUS IN A SAMPLEDecember 2018November 2019Allow1220NoNo
16176461USE OF ADENOVIRUS AND NUCLEIC ACIDS CODING THEREFOROctober 2018March 2020Allow1710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LI, BAO Q.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
1.1%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
35
Allowed After Appeal Filing
15
(42.9%)
Not Allowed After Appeal Filing
20
(57.1%)
Filing Benefit Percentile
70.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner LI, BAO Q - Prosecution Strategy Guide

Executive Summary

Examiner LI, BAO Q works in Art Unit 1671 and has examined 302 patent applications in our dataset. With an allowance rate of 97.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner LI, BAO Q's allowance rate of 97.7% places them in the 89% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LI, BAO Q receive 2.05 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LI, BAO Q is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +1.3% benefit to allowance rate for applications examined by LI, BAO Q. This interview benefit is in the 20% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.5% of applications are subsequently allowed. This success rate is in the 69% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 61.1% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 97.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 84.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 24.5% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.